Management of Pyrexia Associated with the Combined Therapy of BRAF and MEK Inhibitors for Melanoma Patients

DOI Web Site
  • Yoshino Koji
    Department of Dermatologic Oncology, The Cancer Institute Hospital of JFCR

Bibliographic Information

Other Title
  • メラノーマ患者に対するBRAF＋MEK阻害薬併用療法に伴う発熱マネジメント
  • メラノーマ カンジャ ニ タイスル BRAF+MEK ソガイヤク ヘイヨウ リョウホウ ニ トモナウ ハツネツ マネジメント

Search this article

Description

<p>Combined therapies with BRAF and MEK inhibitors are effective treatments for melanoma. However, these therapies are also associated with pyrexia incidence. In this review article, characteristics of pyrexia, such as incidence rate, timing, and recurrence, were reviewed on the basis of reports of clinical trials of BRAF and MEK inhibitors. This article emphasizes key points of pyrexia management in clinical practice, referring to previously reported guidelines, clinical reports, and other review articles. It is expected that the therapeutic outcome of melanoma will be improved further in clinical practice by maximizing the effects of BRAF and MEK inhibitors while managing adverse drug reactions, including pyrexia, appropriately in individual patients.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top